- January 1 to June 30, 2007 revenues were $4,354,609 an increase of 100%
compared to $2,180,577 for the same period in 2006.
- For the three months ended June 30, 2007, revenues increased 72%, from
$1,220,455 in 2006 to $2,102,184 in 2007.
- Net loss amounted to $1,070,192 for the three months ended June 30,
2007, an increase of 112% over the net loss of $505,737 recorded for
the same period in 2006
- Working capital stood at $4.6 million at June 30, 2007.
- Following the close of the quarter, Aptilon completed a public offering
of common shares for aggregate gross proceeds of $10,000,000.
MONTREAL, Aug. 28 /CNW Telbec/ - Aptilon Corporation (TSX.V: APZ)
announced today its results for the three-month period ended June 30, 2007.
Complete financial statements and MD&A are available on SEDAR at
www.sedar.com. Revenues for the period were $2,102,184; an increase of 72%
versus total revenue of $1,220,455 recognized in the three-month period ended
June 30, 2006. Revenues for the six-month period ended June 30, 2007 increased
100% to $4,354,609 when compared to $2,180,577 revenue recognized in the
six-month period ended June 30, 2006.
The net loss for the three-month period ended June 30, 2007 was
$1,070,192 which represents a basic loss per share of $0.0077 (based on a
weighted average number of common shares outstanding of 139,675,857 during the
period. The current number of outstanding shares is 165,367,310.) The
operating loss for the three-month period ended June 30, 2007 is attributed to
additional financing for the growth of physician access, increased G&A
expenses and the incremental commitment in direct sales and marketing efforts.
G&A components contributing to the increase over the previous year, include
$148,038 in stock-based compensation and $139,083 in foreign exchange loss. At
June 30, 2007, the Company's working capital position was $4,607,891 compared
to $5,783,848 at March 31, 2007 and $6,542,888 at December 31, 2006.
"We are pleased with results in the second quarter and by initial
customer adoption of AxcelRx Live 5.0, Aptilon's next generation bundle of
web-based sales and marketing services featuring live sales
representative-physician video detail sessions that was launched during the
period" said Denis Martineau, President of Aptilon. Following the close of the
quarter, on July 9, 2007, Aptilon announced the signing of an important
enterprise commitment with Merck & Co. ("Merck") that expands its contract for
AxcelRx Live video detailing as a component of Merck's alternative sales
Also, following the close of the quarter, on July 19, 2007, Aptilon
completed a public offering of common shares pursuant to which the Company
issued to investors 25,000,000 common shares at a price of $0.40 per common
share, for aggregate gross proceeds of $10,000,000. "By significantly
strengthening its available cash and working capital, Aptilon can now more
rapidly expand the ReachNet recruiting network and thereby increase
availability of sales and marketing interactions to interested, targeted
physicians," Martineau expanded.
Aptilon enables pharmaceutical, biotech and medical device companies to
effectively reach and interact with physicians via the Internet through its
innovative AxcelRx Live video detailing (with company reps), virtual programs,
e-Sampling, peer selling and other sales and marketing programs. Leading
health care companies have adopted Aptilon's "Sales Force of the Future"
model, driving tens of thousands of high-quality rep-physician interactions
averaging 8 to 10 minutes in length. Aptilon provides the infrastructure
necessary for sales representatives to build physician awareness,
understanding and preference during all stages of a products life cycle, from
pre-launch education through end stage support. For more information, visit
This news release contains forward-looking information. These statements
relate to future events or future performance and reflect management's current
expectations and assumptions. Such forward-looking statements reflect
management's current beliefs and are based on information currently available
to management of Aptilon. A number of factors could cause actual events,
performance or results to differ materially from the events performance and
results discussed in the forward-looking statements. These forward-looking
statements are made as of the date hereof and Aptilon does not assume any
obligation to update or revise them to reflect new events or circumstances.
The TSX Venture Exchange has neither approved nor disapproved the
contents of this press release. The TSX Venture Exchange does not accept
responsibility for the adequacy or accuracy of this press release.
For further information:
For further information: Denis Martineau, President, Aptilon, (514)
844-8866, xt 228, email@example.com; Media Relations: Alexandra Malka,
Marketing Communication Specialist, Aptilon, (514) 844-8866, xt 239,